Alpha/Beta Ratio for Normal Lung Tissue as Estimated From Lung Cancer Patients Treated With Stereotactic Body and Conventionally Fractionated Radiation Therapy
Purpose: To estimate the α/β ratio for which the dose-dependent lung perfusion reductions for stereotactic body radiation therapy (SBRT) and conventionally fractionated radiation therapy (CFRT) are biologically equivalent. Methods and Materials: The relations between local dose and perfusion reduction 4 months after treatment in lung cancer patients treated with SBRT and CFRT were scaled according to the linear-quadratic model using α/β ratios from 0 Gy to ∞ Gy. To test for which α/β ratio both treatments have equal biological effect, a 5-parameter logistic model was optimized for both dose–effect relationships simultaneously. Beside the α/β ratio, the other 4 parameters were d{sub 50}, the steepness parameter k, and 2 parameters (M{sub SBRT} and M{sub CFRT}) representing the maximal perfusion reduction at high doses for SBRT and CFRT, respectively. Results: The optimal fitted model resulted in an α/β ratio of 1.3 Gy (0.5-2.1 Gy), M{sub SBRT} = 42.6% (40.4%-44.9%), M{sub CFRT} = 66.9% (61.6%-72.1%), d{sub 50} = 35.4 Gy (31.5-9.2 Gy), and k = 2.0 (1.7-2.3). Conclusions: An equal reduction of lung perfusion in lung cancer was observed in SBRT and CFRT if local doses were converted by the linear-quadratic model with an α/β ratio equal to 1.3 Gy (0.5-2.1 Gy)
- OSTI ID:
- 22283336
- Journal Information:
- International Journal of Radiation Oncology, Biology and Physics, Journal Name: International Journal of Radiation Oncology, Biology and Physics Journal Issue: 1 Vol. 88; ISSN IOBPD3; ISSN 0360-3016
- Country of Publication:
- United States
- Language:
- English
Similar Records
SU-F-T-105: The Predicted Radiation Response of Non-Small Cell Lung Cancer for SRS, SBRT and HDR Brachytherapy
Increasing Radiation Therapy Dose Is Associated With Improved Survival in Patients Undergoing Stereotactic Body Radiation Therapy for Stage I Non–Small-Cell Lung Cancer